Table 1 Patient characteristics
Patient characteristics | r GBM, n = 30 |
|---|---|
Age, years | |
 Mean | 41.8 |
 Median | 43 |
 Range | 21–59 |
Sex, n (%) | |
 Male | 21 (70.0) |
 Female | 9 (30.0) |
Initial KPS, n (%) | |
 50–60 | 8 (26.7) |
 70–80 | 16 (53.3) |
 90–100 | 6 (20.0) |
Relapse, n (%) | |
 First | 16 (53.3) |
 Second | 7 (23.3) |
 Third | 7 (23.3) |
Resection at last relapse before enrollment, n (%) | |
 Yes | 3 (10.0) |
 No | 27 (90.0) |
Previous radiotherapy, n (%) | |
 Yes | 30 (100) |
 No | 0 (0) |
Previous radiation dose, n (%) | |
  > 60Gy | 5 |
 45-60Gy | 24 |
  < 45Gy | 1 |
Number of previous chemotherapy regimens, n (%) | |
 0 | 1 (3.3) |
 1 | 2 (6.7) |
 2 | 13 (43.3) |
 3 | 7 (23.3) |
  ≥ 4 | 7 (23.3) |
Previous chemotherapy regimen, n (%) | |
 Temozolomide, with concomitant radiotherapy | 25 (83.3) |
 Temozolomide | 21 (70.0) |
 Temozolomide + Cisplatin | 4 (13.3) |
 Temozolomide + Carboplatin | 1 (3.3) |
 Temozolomide + Apatinib | 4 (13.3) |
 Temozolomide + Bevacizumab | 2 (6.7) |
 Bevacizumab | 3 (10.0) |
 Temozolomide + Nimotuzumab | 1 (3.3) |
 Lomustine | 1 (3.3) |
 Nimustine | 1 (3.3) |
 Teniposide | 1 (3.3) |
Prior bevacizumab, n (%) | |
 Yes | 5 (16.7) |
 No | 25 (83.3) |
Tumor dissemination, n (%) | |
 Intracranial | 25 (83.3) |
 Intracranial and spinal | 5 (16.7) |
MGMT status, n (%) | |
 Unmethylated | 9 (30) |
 Methylated | 4 (13.3) |
 Not done/unknown | 17 (56.7) |
IDH1/2 mutation, n (%) | |
 Yes | 1 (3.3) |
 No | 10 (33.3) |
 Not done/unknown | 19 (63.3) |
EIAED | 0 (0) |
Non-EIAED | 30 (100) |
Patients alive | 4 (13.3) |
Patients not progressed | 1 (3.3) |
Median treatment length (cycles), range | 2 (1–11) |